がん腫瘍プロファイリングの世界市場レポート 2025年

がん腫瘍プロファイリングの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR14.0％で253億3,000万米ドルに成長します。予測期間の成長は、がん治療における免疫療法と免疫プロファイリングの拡大、リキッドバイオプシーと非侵襲的腫瘍プロファイリング法の開発、より詳細な腫瘍特性分析のためのシングルセルシーケンスの採用、がんスクリーニングと早期発見プログラムの拡大、希少がんと希少がんサブタイププロファイリングに対する需要の増加に起因すると考えられます。予測期間における主要動向には、日常臨床診療への腫瘍プロファイリングの統合、マルチオミクスアプローチの進歩、データ分析における人工知能（AI）と機械学習の統合、個別化医療と標的治療開発、ゲノミクスと次世代シーケンス（NGS）技術の進歩などがあります。

世界のがん罹患率の上昇が、今後のがん・腫瘍プロファイリング市場の成長を牽引すると予想されます。がんは、体内の特定の細胞の制御不能な増殖を特徴とする疾患であり、他の部位に転移する可能性があります。がんの症例数が増加するにつれて、腫瘍プロファイリングの需要も増加し、医師が病気の重症度を評価するのに役立つからです。例えば、米国を拠点とする専門機関である米国がん協会は、2024年に国内で新たに200万人のがん患者が診断され、2023年の190万人から増加したと報告しています。その結果、世界のがん罹患率の増加が、がん腫瘍プロファイリング市場の成長を促進しています。

胃がんの有病率の増加は、がん腫瘍プロファイリング市場の成長の主要な促進要因になると予想されます。胃がんは胃の内壁に悪性細胞が無秩序に増殖するものであり、がん・腫瘍プロファイリングはこの疾患の開発に関する洞察を提供する上で重要な役割を果たします。例えば、胃腸間質腫瘍（GIST）は胃がんとは異なるが胃で発生することがあり、がん・腫瘍プロファイリングはこのような症例の理解と治療に役立ちます。Cancer Research UKが示すように、英国における胃がんの発生率は2023～2025年と2038～2040年の間に12％減少すると予想されています。この減少は好ましいことではあるが、この病気にさらに対処するためには、胃がん研究と腫瘍プロファイリングに引き続き注力する必要性を浮き彫りにしています。このように、胃がんの有病率の増加は、がん腫瘍プロファイリング市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界成長分析と戦略分析フレームワーク

• 世界のがん腫瘍プロファイリング PESTEL分析（政治、社会、技術、環境、法的、促進要因、制約要因）
• 最終用途産業の分析
• 世界のがん腫瘍プロファイリング市場成長率分析
• 世界のがん腫瘍プロファイリング市場の実績：規模と成長、2019～2024年
• 世界のがん腫瘍プロファイリング市場の予測：規模と成長、2024～2029年、2034年
• 世界のがん腫瘍プロファイリング総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがん腫瘍プロファイリング市場：がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 肺がん
• 乳がん
• 大腸がん
• 前立腺がん
• 悪性黒色腫
• 卵巣がん
• 胃がん
• 膵臓がん
• 甲状腺がん
• その他のがんタイプ
• 世界のがん腫瘍プロファイリング市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• 次世代シーケンシング（NGS）
• ポリメラーゼ連鎖反応（PCR）
• 免疫組織化学（IHC）
• in situ-ハイブリダイゼーション（ISH）
• マイクロアレイ
• その他
• 世界のがん腫瘍プロファイリング市場：プロセスタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ゲノミクス
• プロテオミクス
• エピジェネティクス
• メタボロミクス
• その他
• 世界のがん腫瘍プロファイリング市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• パーソナライズ医療
• 診断
• バイオマーカーの発見
• 予測
• 研究用途
• 世界のがん腫瘍プロファイリング市場、肺がんのサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 非小細胞肺がん（NSCLC）
• 小細胞肺がん（SCLC）
• 世界のがん腫瘍プロファイリング市場、乳がんのサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ホルモン受容体陽性
• トリプルネガティブ乳がん
• HER2陽性乳がん
• 世界のがん腫瘍プロファイリング市場、大腸がんのサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 大腸がん
• 直腸がん
• 世界のがん腫瘍プロファイリング市場、前立腺がんのサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 局所性前立腺がん
• 進行性前立腺がん
• 世界のがん腫瘍プロファイリング市場、黒色腫のサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮膚悪性黒色腫
• 非皮膚性黒色腫
• 世界のがん腫瘍プロファイリング市場、卵巣がんのサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 上皮性卵巣がん
• 非上皮性卵巣がん
• 世界のがん腫瘍プロファイリング市場、胃がんのサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 胃腺がん
• 消化管間質腫瘍（GIST）
• 世界のがん腫瘍プロファイリング市場、膵臓がんのサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 外分泌膵臓がん
• 神経内分泌腫瘍
• 世界のがん腫瘍プロファイリング市場、甲状腺がんのサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 甲状腺乳頭がん
• 濾胞性甲状腺がん
• 甲状腺髄様がん
• 世界のがん腫瘍プロファイリング市場、その他のサブセグメンテーション、がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 腎臓がん
• 膀胱がん
• 肝臓がん
• 食道がん

第7章 地域別・国別分析

• 世界のがん腫瘍プロファイリング市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のがん腫瘍プロファイリング市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん腫瘍プロファイリング市場：競合情勢
• がん腫瘍プロファイリング市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • Caris Life Sciences
  • Thermo Fisher Scientific Inc.
  • Illumina Inc.
  • Qiagen

第31章 その他の大手企業と革新的企業

• Ribomed BIoTechnologies Inc.
• HTG Molecular Diagnostics Inc.
• NanoString Technologies Inc.
• NeoGenomics Laboratories Inc.
• Lucence Health Inc.
• ACT Genomics Co. LTD
• Strand Life Sciences
• IMB Dx Inc.
• Exact Sciences Corporation
• Guardant Health
• Foundation Medicine Inc.
• Agilent Technologies Inc.
• Myriad Genetics Inc.
• Personal Genome Diagnostics Inc.
• Tempus Labs Inc.

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、戦略

• がん腫瘍プロファイリング市場、2029年-最も新しい機会を提供する国
• がん腫瘍プロファイリング市場、2029年-最も新しい機会を提供するセグメント
• がん腫瘍プロファイリング市場、2029年-成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Cancer tumor profiling is a laboratory testing method designed to analyze a sample of tumor tissue for specific genes, gene mutations, proteins, or other biomarkers. This comprehensive examination aids in treatment planning and provides valuable insights into the likelihood of cancer recurrence or metastasis.

The primary categories of cancer and tumor profiling encompass lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and various other cancer types. Diverse technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, are employed in this process. These technologies cover multiple facets, including genomics, proteomics, epigenetics, metabolomics, and more. Cancer and tumor profiling find applications in personalized medicine, diagnostics, biomarker discovery, prognostics, and research endeavors.

The cancer tumor profiling market research report is one of a series of new reports from The Business Research Company that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $14.99 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to increasing cancer incidence, growth in precision medicine initiatives and research collaborations, improved cancer diagnostics and early detection methods, availability of a wide range of targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.

The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $25.33 billion in 2029 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to expansion of immunotherapy and immunoprofiling in cancer treatment, development of liquid biopsy and non-invasive tumor profiling methods, adoption of single-cell sequencing for more detailed tumor characterization, expansion of cancer screening and early detection programs, and increasing demand for rare and orphan cancer subtype profiling. Major trends in the forecast period include integration of tumor profiling into routine clinical practice, advances in multi-omics approaches, integration of artificial intelligence (ai) and machine learning in data analysis, personalized medicine and targeted therapy development, and advances in genomics and next-generation sequencing (ngs) technologies.

The rising incidence of cancer worldwide is anticipated to drive the growth of the cancer and tumor profiling market in the future. Cancer is a disease characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas. As the number of cancer cases increases, the demand for tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported that 2 million new cancer cases were diagnosed in the country, an increase from 1.9 million new cases in 2023. Consequently, the increasing incidence of cancer globally is fueling the growth of the cancer and tumor profiling market.

The increasing prevalence of stomach cancer is anticipated to be a key driver for the growth of the cancer and tumor profiling market. Stomach cancer involves the uncontrolled growth of malignant cells in the stomach lining, and cancer and tumor profiling play a crucial role in providing insights into the development of this disease. For example, gastrointestinal stromal tumors (GISTs), though distinct from stomach cancer, can occur in the stomach, and cancer and tumor profiling can help in understanding and treating such cases. As indicated by Cancer Research UK, the incidence of stomach cancer in the UK is expected to decline by 12% between 2023-2025 and 2038-2040. This decline, while positive, highlights the need for continued focus on stomach cancer research and tumor profiling to further address the disease. The growing prevalence of stomach cancer is thus contributing to the expansion of the cancer and tumor profiling market.

Increasing research and development activities are emerging as a significant trend in the cancer and tumor profiling market. Major companies in this sector are prioritizing research and development to meet consumer demands and strengthen their market position. For instance, QIAGEN N.V, a German company specializing in sample and assay technology, recently announced the Conformite Europeenne (CE)-marking and commercialization of the therascreen PIK3CA RGQ PCR Kit in Europe. This diagnostic assay is designed to identify breast cancer patients with PIK3CA mutations, providing crucial information for personalized treatment. The emphasis on research and development activities is a notable trend that is shaping the cancer and tumor profiling market.

In June 2023, Quest Diagnostics, a prominent US-based medical laboratory company, completed the acquisition of Haystack Oncology Inc. for a substantial sum of $450 million. The strategic move by Quest Diagnostics is aimed at broadening access to liquid biopsy technology and strengthening its position in the competitive field of cancer diagnostics. This acquisition is anticipated to augment Quest Diagnostics' research and development capabilities, thereby enhancing its ability to contribute to improved outcomes for cancer patients. Haystack Oncology Inc., based in the United States, is an early-stage oncology company specializing in the development of solid tumor testing technology.

In June 2023, Quest Diagnostics, a US-based medical laboratory firm, acquired Haystack Oncology Inc. for $450 million. This acquisition is intended to broaden access to liquid biopsy technology and enhance Quest Diagnostics' market share in cancer diagnostics by improving research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company focused on developing solid tumor testing technologies aimed at improving outcomes for cancer patients.

Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Tumor Profiling Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer tumor profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer tumor profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer tumor profiling market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types
• 2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies
• 3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types
• 4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications
• Subsegments:
• 1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)
• 2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer
• 3) By Colorectal Cancer: Colon Cancer; Rectal Cancer
• 4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer
• 5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma
• 6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer
• 7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)
• 8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors
• 9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer
• 10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Caris Life Sciences; Thermo Fisher Scientific Inc.; Illumina Inc.; Qiagen
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Tumor Profiling Market Characteristics

3. Cancer Tumor Profiling Market Trends And Strategies

4. Cancer Tumor Profiling Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cancer Tumor Profiling Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer Tumor Profiling PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer Tumor Profiling Market Growth Rate Analysis
• 5.4. Global Cancer Tumor Profiling Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer Tumor Profiling Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer Tumor Profiling Total Addressable Market (TAM)

6. Cancer Tumor Profiling Market Segmentation

• 6.1. Global Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Ovarian Cancer
• Stomach Cancer
• Pancreatic Cancer
• Thyroid Cancer
• Other Cancer Types
• 6.2. Global Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH)
• Microarray
• Other Technologies
• 6.3. Global Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genomics
• Proteomics
• Epigenetics
• Metabolomics
• Other Types
• 6.4. Global Cancer Tumor Profiling Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Personalized Medicine
• Diagnostics
• Biomarker Discovery
• Prognostics
• Research Applications
• 6.5. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Lung Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)
• 6.6. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Breast Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Receptor-Positive
• Triple-Negative Breast Cancer
• HER2-Positive Breast Cancer
• 6.7. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Colorectal Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colon Cancer
• Rectal Cancer
• 6.8. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Prostate Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Localized Prostate Cancer
• Advanced Prostate Cancer
• 6.9. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Melanoma, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cutaneous Melanoma
• Non-Cutaneous Melanoma
• 6.10. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Ovarian Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithelial Ovarian Cancer
• Non-Epithelial Ovarian Cancer
• 6.11. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Stomach Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastric Adenocarcinoma
• Gastrointestinal Stromal Tumors (GISTs)
• 6.12. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Pancreatic Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exocrine Pancreatic Cancer
• Neuroendocrine Tumors
• 6.13. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Thyroid Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Papillary Thyroid Cancer
• Follicular Thyroid Cancer
• Medullary Thyroid Cancer
• 6.14. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Other Cancer Types, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kidney Cancer
• Bladder Cancer
• Liver Cancer
• Esophageal Cancer

7. Cancer Tumor Profiling Market Regional And Country Analysis

• 7.1. Global Cancer Tumor Profiling Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer Tumor Profiling Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Tumor Profiling Market

• 8.1. Asia-Pacific Cancer Tumor Profiling Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Tumor Profiling Market

• 9.1. China Cancer Tumor Profiling Market Overview
• 9.2. China Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Tumor Profiling Market

• 10.1. India Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Tumor Profiling Market

• 11.1. Japan Cancer Tumor Profiling Market Overview
• 11.2. Japan Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Tumor Profiling Market

• 12.1. Australia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Tumor Profiling Market

• 13.1. Indonesia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Tumor Profiling Market

• 14.1. South Korea Cancer Tumor Profiling Market Overview
• 14.2. South Korea Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Tumor Profiling Market

• 15.1. Western Europe Cancer Tumor Profiling Market Overview
• 15.2. Western Europe Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Tumor Profiling Market

• 16.1. UK Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Tumor Profiling Market

• 17.1. Germany Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Tumor Profiling Market

• 18.1. France Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Tumor Profiling Market

• 19.1. Italy Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Tumor Profiling Market

• 20.1. Spain Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Tumor Profiling Market

• 21.1. Eastern Europe Cancer Tumor Profiling Market Overview
• 21.2. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Tumor Profiling Market

• 22.1. Russia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Tumor Profiling Market

• 23.1. North America Cancer Tumor Profiling Market Overview
• 23.2. North America Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Tumor Profiling Market

• 24.1. USA Cancer Tumor Profiling Market Overview
• 24.2. USA Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Tumor Profiling Market

• 25.1. Canada Cancer Tumor Profiling Market Overview
• 25.2. Canada Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Tumor Profiling Market

• 26.1. South America Cancer Tumor Profiling Market Overview
• 26.2. South America Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Tumor Profiling Market

• 27.1. Brazil Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Tumor Profiling Market

• 28.1. Middle East Cancer Tumor Profiling Market Overview
• 28.2. Middle East Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Tumor Profiling Market

• 29.1. Africa Cancer Tumor Profiling Market Overview
• 29.2. Africa Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Tumor Profiling Market Competitive Landscape And Company Profiles

• 30.1. Cancer Tumor Profiling Market Competitive Landscape
• 30.2. Cancer Tumor Profiling Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Caris Life Sciences Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Qiagen Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Tumor Profiling Market Other Major And Innovative Companies

• 31.1. Ribomed Biotechnologies Inc.
• 31.2. HTG Molecular Diagnostics Inc.
• 31.3. NanoString Technologies Inc.
• 31.4. NeoGenomics Laboratories Inc.
• 31.5. Lucence Health Inc.
• 31.6. ACT Genomics Co. LTD
• 31.7. Strand Life Sciences
• 31.8. IMB Dx Inc.
• 31.9. Exact Sciences Corporation
• 31.10. Guardant Health
• 31.11. Foundation Medicine Inc.
• 31.12. Agilent Technologies Inc.
• 31.13. Myriad Genetics Inc.
• 31.14. Personal Genome Diagnostics Inc.
• 31.15. Tempus Labs Inc.

32. Global Cancer Tumor Profiling Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Tumor Profiling Market

34. Recent Developments In The Cancer Tumor Profiling Market

35. Cancer Tumor Profiling Market High Potential Countries, Segments and Strategies

• 35.1 Cancer Tumor Profiling Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer Tumor Profiling Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer Tumor Profiling Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer